222 related articles for article (PubMed ID: 18039557)
1. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
Zhang J; Wang X; Lu H
Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase.
Wang Y; Lu H; Wang D; Li S; Sun K; Wan X; Taylor EW; Zhang J
Toxicol Appl Pharmacol; 2012 Dec; 265(3):342-50. PubMed ID: 22982619
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
5. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy.
Wang X; Zhang J; Xu T
Eur J Pharmacol; 2008 Jan; 579(1-3):66-73. PubMed ID: 18028906
[TBL] [Abstract][Full Text] [Related]
7. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity.
Zhang J; Lu H
Free Radic Biol Med; 2007 Dec; 43(12):1574-83. PubMed ID: 18037123
[TBL] [Abstract][Full Text] [Related]
9. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
10. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
12. [Suppression of CDDP-induced renal toxicity by sodium selenite].
Yokoyama M; Naganuma A; Imura N
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1225-30. PubMed ID: 4057578
[TBL] [Abstract][Full Text] [Related]
13. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
14. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
[TBL] [Abstract][Full Text] [Related]
15. Attenuating the toxicity of cisplatin by using selenosulfate with reduced risk of selenium toxicity as compared with selenite.
Zhang J; Peng D; Lu H; Liu Q
Toxicol Appl Pharmacol; 2008 Feb; 226(3):251-9. PubMed ID: 17950769
[TBL] [Abstract][Full Text] [Related]
16. [A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites].
Shindoh T; Matsuura N; Sugitachi A; Saitoh K
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2195-8. PubMed ID: 12484035
[TBL] [Abstract][Full Text] [Related]
17. 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage.
Zhou B; Huang J; Zuo Y; Li B; Guo Q; Cui B; Shao W; Du J; Bu X
Eur J Pharmacol; 2013 May; 707(1-3):130-9. PubMed ID: 23524096
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]